Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Ending Cash Position : HK$10,394 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position?

Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position for the quarter that ended in Dec. 2023 was HK$10,394 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's quarterly Ending Cash Position declined from Jun. 2023 (HK$13,190 Mil) to Sep. 2023 (HK$10,815 Mil) and declined from Sep. 2023 (HK$10,815 Mil) to Dec. 2023 (HK$10,394 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual Ending Cash Position increased from Dec. 2021 (HK$7,910 Mil) to Dec. 2022 (HK$12,474 Mil) but then declined from Dec. 2022 (HK$12,474 Mil) to Dec. 2023 (HK$10,394 Mil).

Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

9,218.44

8,683.15

7,909.71

12,473.78

10,393.51

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															12,473.78	13,805.46	13,190.31	10,815.20	10,393.51

Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	12217.584	+	-1824.072
	=	10,394

Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	11027.654	+	-634.142
	=	10,394

Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (HKSE:02196) » Definitions » Ending Cash Position

Traded in Other Exchanges

SFOSF:USA 08HH:Germany 600196:China

Address

No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233

Website

https://www.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Headlines

No Headlines